Shanghai Yizhong Pharmaceutical Co., Ltd.

SHSE:688091 Stock Report

Mkt Cap: CN¥12.6b

We’ve recently updated our valuation analysis.

Shanghai Yizhong Pharmaceutical Valuation

Is 688091 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 0/6

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688091?

Other financial metrics that can be useful for relative valuation.

688091 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue48.8x
Enterprise Value/EBITDA99.3x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 688091's PE Ratio compare to its peers?

The above table shows the PE ratio for 688091 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average46.4x
688578 Shanghai Allist Pharmaceuticals
300181 Zhejiang Jolly PharmaceuticalLTD
688356 Jenkem Technology
300573 Shenyang Xingqi PharmaceuticalLtd
688091 Shanghai Yizhong Pharmaceutical

Price to Earnings Ratio vs Industry

How does 688091's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.1%
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.1%
No more companies

Price to Earnings Ratio vs Fair Ratio

What is 688091's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688091 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio88.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 688091's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 688091 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies